Doff Biotech

Doff Biotech is a clinical-stage biotechnology company based in Beijing, China, dedicated to the research and development of innovative immune cell therapies. As the life sciences subsidiary of the Doff Group, the company leverages advanced CAR-T and TCR-T platforms to address unmet needs in oncology and hematology. Its lead program, DF-003, is a BCMA-targeted CAR-T therapy currently in Phase 1/2 clinical trials for the treatment of relapsed or refractory multiple myeloma. Doff Biotech is also advancing a pipeline of candidates targeting CD19 and other antigens for various hematological malignancies. The company's mission is to provide accessible and highly effective cell-based treatments for cancer patients globally. Through its proprietary technology, Doff Biotech aims to optimize the safety and efficacy profiles of next-generation cell products.